<DOC>
	<DOC>NCT02392117</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba速) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes mellitus.</brief_summary>
	<brief_title>Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Informed consent obtained before any studyrelated activities (Studyrelated activities are any procedure related to recording of data according to the protocol) Male or female patients at least 18 years of age at time of informed consent T1DM (diagnosed clinically) prior to inclusion in the study, and/or T2DM, insulin using patients (diagnosed clinically) prior to inclusion in the study Planned initiation with Tresiba速 Known or suspected hypersensitivity to Tresiba速 or any of the excipients listed in Section 6.1 of the SmPC (Summary of Product Characteristics) or related products Previous participation in this study (i.e. provision of informed consent) Patients who have previously been treated with Tresiba速 Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>